SPF harmonization
This article was originally published in The Rose Sheet
Executive Summary
The International Sun Protection Factor (SPF) Test Method, which sets a basis for harmonized strategy for substantiating claims on sun protection products worldwide, will initially be implemented in the EU, Japan and South Africa, the European Cosmetic, Toiletry and Perfumery Association announces. The industries, represented by their respective trade associations and joined by the U.S., signed the agreement June 1. More countries are expected to join the agreement, Colipa notes. In the U.S., FDA prescribes a method that differs "slightly," but the U.S. industry "supports and promotes the international method as the appropriate standard that all regulatory frameworks should move towards," Colipa adds. The industries of the four countries also will promote the test method as a standard of the International Standards Organization. In light of the agreement, "consumers can be assured that the same high-quality testing standard has been applied regardless of the country where they buy the products and authorities will have a tool to control the substantiation of SPF claims made by companies," Colipa adds...
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.